The Medical Letter - 2007
Search or Select Article Below and Click to Purchase
Year:    Publication:      2007 Annual Index: U.S. English | Canadian English
January 1, 2007 (Issue 1251)  
  • Sitagliptin (Januvia) for Type 2 Diabetes
    Sitagliptin phosphate (Januvia - Merck) is the first dipeptidyl-peptidase-4 (DPP-4) inhibitor to be marketed for treatment of type 2 diabetes. It has been approved by the FDA for oral use as...
  • Oral Oxymorphone (Opana)
    Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been...
January 15, 2007 (Issue 1252)  
  • A Low-Dose Doxycycline (Oracea) for Rosacea
    A new once-daily, low-dose oral formulation of doxycycline monohydrate (Oracea - CollaGenex) has been approved by the FDA for treatment of inflammatory papules and pustules associated with...
  • Dasatinib (Sprycel) for CML and Ph+ ALL
    Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and...
  • Tdap, DTaP Mix-Ups
    Medical Letter consultants have brought to our attention some confusion that has accompanied the release of Adacel, a combination of tetanus toxoid, diphtheria toxoid and acellular...
January 29, 2007 (Issue 1253)  
  • Pioglitazone/Glimepiride (Duetact) for Diabetes
    Duetact (Takeda), a new fixed-dose combination of the thiazolidinedione pioglitazone (Actos) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the...
  • Telbivudine (Tyzeka) for Chronic Hepatitis B
    The FDA has approved the nucleoside analog telbivudine (Tyzeka - Novartis/Idenix) for treatment of patients ≥16 years old with active chronic hepatitis B virus (HBV) infection. It is the...
  • Clarification: Hand Hygiene and CDAD
    In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile...
February 12, 2007 (Issue 1254)  
  • Continuous Glucose Monitoring
    A variety of glucose monitoring devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical...
  • Angeliq for Treatment of Menopausal Symptoms
    A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus....
February 26, 2007 (Issue 1255)  
  • Proton Pump Inhibitors for GERD in Children
    A recent advertisement for the proton pump inhibitor (PPI) lansoprazole (Prevacid - TAP) suggests that children who cough at night, complain of abdominal pain, refuse to eat, or have a bad...
  • Two New Drugs for Renal Cell Carcinoma
    Sunitinib (Sutent - Pfizer) and sorafenib (Nexavar - Bayer), two oral tyrosine kinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma (RCC)....
  • In Brief: Femcon Fe: A Chewable Oral Contraceptive
    Femcon Fe (Warner Chilcott) is being advertised as the world's only chewable oral contraceptive. It was formerly marketed as Ovcon 35 Fe. Each packet provides 21 tablets containing 0.4 mg...
March 12, 2007 (Issue 1256)  
  • Paliperidone (Invega) for Schizophrenia
    Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation...
  • Vorinostat (Zolinza) for Cutaneous T-cell Lymphoma
    Vorinostat (Zolinza - Merck), an oral histone deacetylase (HDAC) inhibitor, has received accelerated approval from the FDA for treatment of skin manifestations of cutaneous T-cell lymphoma...
March 26, 2007 (Issue 1257)  
April 9, 2007 (Issue 1258)  
  • Aliskiren (Tekturna) for Hypertension
    Aliskiren (ah LIS ker in; Tekturna - Novartis), the first direct renin inhibitor, has been approved by the FDA for treatment of hypertension. It is indicated for oral use either as...
  • Subcutaneous Immune Globulin (SCIG)
    Some patients with primary immune deficiency are injected with intravenous immune globulin (IVIG) every 3-4 weeks. Now a subcutaneous immune globulin (SCIG) has also been approved in the US for this...
April 23, 2007 (Issue 1259)  
  • Drugs for Female Sexual Dysfunction
    Superseded by The Medical Letter "Drugs for Female Sexual Dysfunction" - Issue 1353, December 13, 2010Sexual complaints related to desire, arousal, orgasm and pain are common in women. No...
  • Panitumumab (Vectibix) for Metastatic Colorectal Cancer
    Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of...
May 7, 2007 (Issue 1260)  
  • Erythropoietin Safety Concerns
    The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood...
  • Dermal Fillers
    Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
  • In Brief: Tegaserod (Zelnorm) Withdrawn
    Tegaserod maleate (Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of...
May 20, 2007 (Issue 1261)  
  • A New Sunscreen Agent
    Ecamsule (terephthalylidene dicamphor sulfonic acid), the first new sunscreen agent to be approved by the FDA in 18 years, is now available in the US in a moisturizer called Anthelios SX....
  • Insulin-like Growth Factor-1 for Severe Growth Failure
    Mecasermin (Increlex - Tercica), which is injected subcutaneously, has been approved by the FDA for treatment of growth failure in children with severe primary insulin-like growth factor...
June 4, 2007 (Issue 1262)  
  • Sitagliptin/Metformin (Janumet) for Type 2 Diabetes
    Sitagliptin (Januvia) and metformin (Glucophage, and others) are now available in a single tablet (Janumet - Merck) for treatment of type 2 diabetes. The combination is approved...
  • MoviPrep: A New Bowel Prep for Colonoscopy
    MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional...
  • In Brief: Toxicity of Gadolinium-Based Contrast Agents
    Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based...
  • Correction: Panitumumab Dosage
    In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
June 18, 2007 (Issue 1263)  
  • Treatment of Lyme Disease
    Superseded by The Medical Letter "Treatment of Lyme Disease" - Issue 1494, May 9, 2016Most cases of Lyme disease in North America occur between May and September. In 2005, 12 states (CT, DE,...
  • ThermaClear for Acne
    The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate...
  • In Brief: Orlistat OTC for Weight Loss
    The FDA has approved over-the-counter (OTC) sale of the weight-loss drug orlistat (Xenical – Roche)1 as alli (GlaxoSmithKline), to be used in combination with a reduced-calorie,...
July 2, 2007 (Issue 1264)  
  • Arformoterol (Brovana) for COPD
    Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of...
  • Resperate for Hypertension
    The FDA has approved the marketing of Resperate (InterCure), a device that helps patients breathe slowly, as an adjunct for treatment of hypertension. The FDA does not require proof of...
  • In Brief: Testing for Ovarian Cancer
    Recent publicity about symptoms of ovarian cancer will prompt many questions from patients about testing for the disease. Early-stage epithelial ovarian cancer is potentially curable, with survival...
July 16, 2007 (Issue 1265)  
  • Thiazolidinediones and Cardiovascular Disease
    The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) are peripheral insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes; one or...
  • Lisdexamfetamine dimesylate (Vyvanse) for ADHD
    Lisdexamfetamine dimesylate (Vyvanse - Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity...
  • In Brief: Anaphylaxis with Omalizumab (Xolair)
    The FDA has received new reports of serious and life-threatening hypersensitivity reactions to omalizumab (Xolair – Genentech), a monoclonal anti-IgE antibody injected subcutaneously for...
  • Addendum: Dermal Fillers
    Some Medical Letter consultants have suggested that our recent article on dermal fillers (Med Lett Drugs Ther 2007; 49:39) should have included stronger warnings about the risk of fillers that are...
July 30, 2007 (Issue 1266)  
  • Lybrel - A Continuous Oral Contraceptive
    Lybrel (Wyeth) is the first FDA-approved low-dose combination oral contraceptive taken 365 days a year without a placebo or pill-free interval. All tablets contain low doses of levonorgestrel...
  • Drugs for Community-Acquired Bacterial Pneumonia
    Most patients with community-acquired pneumonia (CAP) are treated empirically. New guidelines published jointly by the Infectious Diseases Society of America and the American Thoracic Society have...
  • Corrections: Lyme Disease
    Superseded by The Medical Letter "Treatment of Lyme Disease" - Issue 1494, May 9, 2016(Med Lett Drugs Ther 2007; 49:49) The PR interval in the table on page 50 and at the top of the first...
August 13, 2007 (Issue 1267)  
  • Reducing Intake of Trans Fatty Acids
    The New York City Board of Health has recently required that city restaurants reduce the content of industrially produced trans fatty acids so that each serving contains
  • Probiotics
    Superseded by The Medical Letter "Probiotics Revisited" - Issue 1407, January 7, 2013Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) that have been used for...
August 27, 2007 (Issue 1268)  
  • Transdermal Rotigotine (Neupro) for Parkinson's Disease
    Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
  • Low-Dose Transdermal Estrogens
    Three low-dose transdermal estrogens were recently approved by the FDA for treatment of menopausal vasomotor symptoms. Elestrin and Divigel are transdermal estradiol gels and Evamist...
  • Correction: Resperate for Hypertension
    (Med Lett Drugs Ther 2007; 49:55) The second sentence in the article ("The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.")...
September 10, 2007 (Issue 1269)  
September 24, 2007 (Issue 1270)  
October 8, 2007 (Issue 1271)  
  • Influenza Vaccine 2007-2008
    Superseded by The Medical Letter "Influenza Vaccine for 2018-2019" - Issue 1558, October 22, 2018Annual immunization against influenza A and B is the most effective method of preventing...
  • Blood Test for Tuberculosis
    Quantiferon - TB Gold (Cellestis) is a T-cell interferon-gamma release assay approved by the FDA as an alternative to the tuberculin skin test for diagnosis of infection with Mycobacterium...
  • Addendum: Sunscreens and DEET
    Superseded by The Medical Letter "Sunscreens" - Issue 1553, August 13, 2018An article (Med Lett Drugs Ther 2007; 49:41) on sunscreens in the May 21 issue of The Medical Letter included...
  • Correction: Low Dose Transdermal Estrogens
    The Medical Letter article (Med Lett Drugs Ther 2007; 49:71) on Low-Dose Transdermal Estrogens said that Elestrin has been marketed in Europe since 1976. Actually it is EstroGel...
October 22, 2007 (Issue 1272)  
  • Antiviral Drugs for Influenza
    Superseded by The Medical Letter "Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza" - Issue 1563, January 14, 2019Antiviral drugs can be used for treatment of patients with...
  • Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
    Ambrisentan (Letairis - Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III)...
November 5, 2007 (Issue 1273)  
November 19, 2007 (Issue 1274)  
  • BRCA Screening
    Direct-to-consumer advertisements are urging women to be tested for mutations in BRCA1 and BRCA2 genes, which are the most common known causes of an inherited predisposition to breast...
  • Formoterol (Perforomist) for COPD
    Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of...
  • SSRIs and Osteoporosis
    Some recently published studies suggest that taking selective serotonin reuptake inhibitors (SSRIs) may increase the risk of developing osteoporosis. A relationship between SSRIs and osteoporosis is...
  • In Brief: Varenicline (Chantix) Revisited
    When the nicotine receptor partial agonist varenicline (Chantix – Pfizer) was first marketed, The Medical Letter concluded that it was moderately effective in increasing smoking...
December 3, 2007 (Issue 1275)  
December 17, 2007 (Issue 1276)